Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 5.31B 787M 684M 636M 585M 1.11B 75.09B 1.12B 7.5B 2.95B 37.46B 2.96B 2.89B 124B P/E 2026 *
5.56x
P/E 2027 * 4.95x
Enterprise Value 5.31B 787M 684M 636M 585M 1.11B 75.09B 1.12B 7.5B 2.95B 37.46B 2.96B 2.89B 124B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.63x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
3 years 18.53
Extreme 18.53
27.85
5 years 12.12
Extreme 12.12
27.85
10 years 12.12
Extreme 12.12
27.85
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 2019-11-30
Comptroller/Controller/Auditor 53 2011-01-31
Director TitleAgeSince
Chairman 70 2002-08-13
Director/Board Member 62 2002-08-13
Director/Board Member 58 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.89%-.--% - - 802M
-0.53%+1.87%+14.81%+74.83% 50.29B
-1.81%+1.69%+53.40%+106.05% 37.24B
+0.46%+5.76%-5.53%+25.08% 12.41B
+1.05%+1.17%+13.23%+75.93% 11.65B
+0.19%+0.57%+32.24%+132.30% 9.17B
-2.99%-0.60%+43.05%-8.54% 7.24B
+0.51%+1.29%+14.45%+34.63% 6.8B
+1.99%+1.31%+3.73%+179.67% 6.47B
+0.39%-4.81%-34.14%-1.07% 5.46B
Average +0.32%+1.96%+15.03%+68.76% 16.3B
Weighted average by Cap. -0.50%+2.71%+22.91%+78.05%

Financials

2026 *2027 *
Net sales 3.03B 450M 391M 364M 334M 631M 42.9B 641M 4.29B 1.68B 21.4B 1.69B 1.65B 70.8B 3.26B 484M 420M 391M 359M 679M 46.14B 689M 4.61B 1.81B 23.02B 1.82B 1.78B 76.15B
Net income 956M 142M 123M 115M 105M 199M 13.52B 202M 1.35B 530M 6.74B 532M 521M 22.31B 1.07B 159M 138M 128M 118M 223M 15.16B 226M 1.51B 595M 7.56B 597M 584M 25.02B
Net Debt - -
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,822
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
7.029CNY
Average target price
7.943CNY
Spread / Average Target
+13.00%

Quarterly revenue - Rate of surprise